Danish drugmaker Lundbeck is set to buy Bothell, Wash.-based Alder Biopharmaceuticals in a deal that could be worth up to $1.95 billion, sending Alder’s stock rocketing up 83 percent on… Read More
Alder BioPharmaceuticals has raised $170 million in a stock offering and is ramping up operations after filing an FDA application for eptinezumab, a therapy for patients with chronic migraines. Alder… Read More